Virtual screening and fragment-based screening methods, including Weak Affinity Chromatography (WAC), are efficient and informed methods for hit identification. However, advancing drug discovery programs beyond the initial screening hits remains a challenge. Employing workflows that fully leverage available data maximize the chances of success and can uncover new opportunities.
In this webinar, Dr. Björn Borgström will share real-world examples of how innovative and resource-efficient workflows have been used by the Drug Discovery Team at RG Discovery to overcome challenges and accelerate project progression. Through case studies, attendees will gain practical insights into decision-making processes that enable rapid and cost-effective advancement of drug discovery programs.
Key Learning Objectives:
- Creative and pragmatic approaches to kickstart projects in early-stage drug discovery programs.
- Strategies for efficient hit identification, illustrated through case studies targeting CDK9 and SMARCA4.
- How CETSA-based selectivity profiling can reveal potential liabilities and identify opportunities early in a project.
Featuring Insights from
Björn Borgström
PhD
Dr. Björn Borgström is head of Drug Discovery at RG Discovery. Since joining the company as a Medicinal Chemist following his graduation from Lund University, Sweden, he has played a key role in advancing drug discovery programs across multiple therapeutic areas. Over the past decade, he has led and contributed to projects from hit identification through lead optimization, supporting the development of novel therapies for oncology, metabolic diseases, and inflammatory disorders. He has co-authored 10 peer-reviewed publications and is an inventor on five patents.
Sponsored by
RG Discovery
.avif)
.avif)
